MXPA04004747A - Forma de dosificacion farmaceutica con multiples recubrimientos. - Google Patents

Forma de dosificacion farmaceutica con multiples recubrimientos.

Info

Publication number
MXPA04004747A
MXPA04004747A MXPA04004747A MXPA04004747A MXPA04004747A MX PA04004747 A MXPA04004747 A MX PA04004747A MX PA04004747 A MXPA04004747 A MX PA04004747A MX PA04004747 A MXPA04004747 A MX PA04004747A MX PA04004747 A MXPA04004747 A MX PA04004747A
Authority
MX
Mexico
Prior art keywords
coating layer
poly
methacrylic acid
methyl methacrylate
outer coating
Prior art date
Application number
MXPA04004747A
Other languages
English (en)
Spanish (es)
Inventor
Tony Ryan Cronk
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32823137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04004747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MXPA04004747A publication Critical patent/MXPA04004747A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA04004747A 2001-11-23 2001-11-23 Forma de dosificacion farmaceutica con multiples recubrimientos. MXPA04004747A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/043893 WO2003045356A1 (en) 2000-11-20 2001-11-23 Pharmaceutical dosage form with multiple coatings

Publications (1)

Publication Number Publication Date
MXPA04004747A true MXPA04004747A (es) 2004-08-02

Family

ID=32823137

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004747A MXPA04004747A (es) 2001-11-23 2001-11-23 Forma de dosificacion farmaceutica con multiples recubrimientos.

Country Status (15)

Country Link
EP (1) EP1453487B2 (enExample)
JP (1) JP4999037B2 (enExample)
CN (1) CN1314390C (enExample)
AT (1) ATE389389T1 (enExample)
AU (1) AU2002226955B2 (enExample)
BR (1) BRPI0117180B8 (enExample)
DE (1) DE60133319T3 (enExample)
DK (1) DK1453487T3 (enExample)
ES (1) ES2301575T5 (enExample)
HU (1) HU231030B1 (enExample)
IL (1) IL161628A (enExample)
MX (1) MXPA04004747A (enExample)
NZ (1) NZ532564A (enExample)
PT (1) PT1453487E (enExample)
WO (1) WO2003045356A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PT2446881E (pt) * 2003-07-24 2014-06-11 Glaxosmithkline Llc Películas de dissolução oral
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
ES2323536T3 (es) * 2004-09-01 2009-07-20 The Procter And Gamble Company Composiciones que comprenden acido-5-amino-2-hidroxibenzoico yh un azucar reductor.
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2012107058A (ja) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc 複数のコーティングを有する医薬剤形
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
GB2510754B (en) * 2013-02-12 2016-07-13 Diurnal Ltd Controlled drug release
TWI688411B (zh) * 2013-02-22 2020-03-21 日商志瑞亞新藥工業股份有限公司 腸溶錠
JP6165022B2 (ja) * 2013-10-30 2017-07-19 株式会社ファンケル 放出制御型ソフトカプセル剤
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
CN107661370A (zh) * 2017-11-20 2018-02-06 贵州浩诚药业有限公司 一种苦参片及其制备方法
JP2021528483A (ja) * 2018-05-03 2021-10-21 エムダブリュ エンキャップ リミテッド 下部胃腸管への医薬の送達のための剤形
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
CN113993509A (zh) * 2019-05-15 2022-01-28 赢创运营有限公司 用胶囊填充机制备具有基于(甲基)丙烯酸酯共聚物的包衣的填充硬壳胶囊的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets

Also Published As

Publication number Publication date
DK1453487T3 (da) 2008-07-21
ES2301575T5 (es) 2022-04-22
AU2002226955A1 (en) 2003-06-10
IL161628A0 (en) 2004-09-27
EP1453487B1 (en) 2008-03-19
DE60133319D1 (de) 2008-04-30
NZ532564A (en) 2006-06-30
HUP0402230A2 (hu) 2005-02-28
BRPI0117180B1 (pt) 2018-12-04
WO2003045356A1 (en) 2003-06-05
BRPI0117180B8 (pt) 2021-05-25
EP1453487B2 (en) 2021-03-31
HUP0402230A3 (en) 2008-04-28
ATE389389T1 (de) 2008-04-15
BR0117180A (pt) 2004-11-03
AU2002226955B2 (en) 2006-04-27
DE60133319T2 (de) 2009-04-30
DE60133319T3 (de) 2021-08-05
CN1314390C (zh) 2007-05-09
HU231030B1 (hu) 2019-12-30
CN1558754A (zh) 2004-12-29
JP4999037B2 (ja) 2012-08-15
ES2301575T3 (es) 2008-07-01
JP2005510539A (ja) 2005-04-21
PT1453487E (pt) 2008-05-13
IL161628A (en) 2014-03-31
EP1453487A1 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
IL161628A0 (en) Pharmaceutical dosage form with multiple coatings
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
US6103266A (en) Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US5686094A (en) Controlled release formulations for the treatment of xerostomia
WO2004108162A3 (en) Controlled release pharmaceutical composition
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
ATE213936T1 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
JPH059412B2 (enExample)
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
EP0497956B1 (en) Controlled release formulations
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
CA2415957A1 (en) Dry powder formulation comprising racecadotril
US20200323834A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof
JP2021535163A5 (enExample)
CA2444814A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2000047232A1 (fr) Implant a liberation prolongee, son procede de preparation et traitement du cancer
CA2472449A1 (en) Pharmaceutical composition for oral use with improved absorption

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights